Press release
Familial Adenomatous Polyposis Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
"DelveInsight's, "Familial adenomatous polyposis Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Familial adenomatous polyposis pipeline landscape. It covers the Familial Adenomatous Polyposis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Adenomatous Polyposis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Explore our latest breakthroughs in Familial Adenomatous Polyposis Research. Learn more about our innovative pipeline today! @ Familial Adenomatous Polyposis Pipeline Outlook- https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Familial Adenomatous Polyposis Pipeline Report
• In July 2025, Parabilis Medicines Inc. announced a Phase 1/2, multicenter, open-label, non-randomized, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and antitumor activity of FOG-001 as monotherapy and in combination with other anticancer agents in participants with advanced or metastatic solid tumors likely or known to have a Wnt pathway activating mutation (WPAM).
• DelveInsight's Familial Adenomatous Polyposis pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Familial Adenomatous Polyposis treatment.
• The leading Familial Adenomatous Polyposis Companies such as SLA Pharma, Recursion Pharmaceuticals, TherapyX, Eloxx Pharmaceuticals and others.
• Promising Familial Adenomatous Polyposis Pipeline Therapies such as Eicosapentaenoic acid free fatty acid (EPA-FFA), REC-4881, Encapsulated Rapamycin (eRapa), Eflornithine, Sulindac 150 MG, Eicosapentanoic Acid (EPA), FOG-001, Nivolumab, mFOLFOX-6 and others.
Stay informed about the cutting-edge advancements in Familial Adenomatous Polyposis treatments. Download for updates and be a part of the revolution in Genetic Disease Care @ Familial Adenomatous Polyposis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Familial Adenomatous Polyposis Emerging Drugs Profile
• ALFA: SLA Pharma
ALFA is a unique, novel oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules that is delivered to the gut at optimal pH allowing maximal absorption. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Familial adenomatous polyposis.
• REC-4881: Recursion Pharmaceuticals
REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Familial adenomatous polyposis.
The Familial Adenomatous Polyposis Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Familial Adenomatous Polyposis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Familial Adenomatous Polyposis Treatment.
• Familial Adenomatous Polyposis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Familial Adenomatous Polyposis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Familial Adenomatous Polyposis market.
Learn more about Familial Adenomatous Polyposis Drugs opportunities in our groundbreaking Familial Adenomatous Polyposis research and development projects @ Familial Adenomatous Polyposis Unmet Needs- https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Familial Adenomatous Polyposis Companies
SLA Pharma, Recursion Pharmaceuticals, TherapyX, Eloxx Pharmaceuticals and others.
Familial adenomatous polyposis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Familial Adenomatous Polyposis Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide
Discover the latest advancements in Familial Adenomatous Polyposis treatment by visiting our website. Stay informed about how we're transforming the future of Genetic Disease @ Familial Adenomatous Polyposis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Familial Adenomatous Polyposis Pipeline Report
• Coverage- Global
• Familial Adenomatous Polyposis Companies- SLA Pharma, Recursion Pharmaceuticals, TherapyX, Eloxx Pharmaceuticals and others.
• Familial Adenomatous Polyposis Pipeline Therapies- Eicosapentaenoic acid free fatty acid (EPA-FFA), REC-4881, Encapsulated Rapamycin (eRapa), Eflornithine, Sulindac 150 MG, Eicosapentanoic Acid (EPA), FOG-001, Nivolumab, mFOLFOX-6 and others.
• Familial Adenomatous Polyposis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Familial Adenomatous Polyposis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Familial Adenomatous Polyposis Pipeline on our website @ Familial Adenomatous Polyposis Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/familial-adenomatous-polyposis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Introduction
2. Executive Summary
3. Familial Adenomatous Polyposis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Familial Adenomatous Polyposis- DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Familial Adenomatous Polyposis Collaboration Deals
9. Late Stage Products (Phase III)
10. ALFA: SLA Pharma
11. Drug profiles in the detailed report.....
12. Mid Stage Products (Phase II)
13. REC-4881: Recursion Pharmaceuticals
14. Drug profiles in the detailed report.....
15. Early Stage Products (Phase I)
16. Drug name: Company name
17. Drug profiles in the detailed report.....
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report.....
21. Inactive Products
22. Familial Adenomatous Polyposis Key Companies
23. Familial Adenomatous Polyposis Key Products
24. Familial Adenomatous Polyposis - Unmet Needs
25. Familial Adenomatous Polyposis - Market Drivers and Barriers
26. Familial Adenomatous Polyposis - Future Perspectives and Conclusion
27. Familial Adenomatous Polyposis Analyst Views
28. Familial Adenomatous Polyposis Key Companies
29. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Familial Adenomatous Polyposis Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4106705 • Views: …
More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…

Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…

Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…

Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Familial
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…